Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
This study evaluates whether there are pre-treatment factors such as patient characteristics, specific breast cancer type, specific treatments, toxicities, or adverse events during treatment that may impact the quality of life and function, 3 years or more after the treatment, in cancer-free subjects. There will be 2 groups. Cohort A: Women who participated in previous studies namely NCT02167932, NCT02328313, and NCT03761706, will be re-contacted and consent for this study activities. Cohort B: Women with breast cancer, who did not receive chemotherapy, will be consented to be included in the study, and their electronic medical data will be used. Furthermore, the long-term effects of treatment and a biomarker of aging cyclin-dependent kinase inhibitor 2A (CDKN2A,p16INK4a) and relation will be assessed.
⁃ In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
• Informed consent was obtained per Institutional Review Board guidelines to participate in the study and HIPAA authorization for the release of personal health information.
• Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.
• Age ≥21 years at the time of consent.
• Able to read and comprehend English.
• No breast cancer recurrence or metastasis; no other cancer diagnosis other than basal cell or squamous cell cancers.